October 6, 2014

UGent spin-off Biogazelle attracts new investors QBIC Arkiv Fund, Foundation Majoie and SOFI to finance growth

Qbic Arkiv Fund, Foundation Majoie and SOFI invest 2.0 million EUR in UGent spin-off Biogazelle, a company that offers software and laboratory services for gene expression analysis. Biogazelle will primarily use the investment to further develop its research on therapeutic RNA targets for specific cancer types, and to expand its commercial activities.

October 1, 2013

Biogazelle serves as reference laboratory for Bio-Rad's droplet digital PCR system

Biogazelle today annouced that it is serving is a reference laboratory for Bio‑Rad’s QX200™ Digital Droplet PCR™ system (ddPCR) in Europe. This extends Biogazelle’s and Bio-Rad’s long-term partnership for PCR-based solutions. As a reference laboratory, Biogazelle uses ddPCR in its R&D programs and shares its ddPCR user experience with the PCR community. In addition, Biogazelle is acting as a ddPCR service provider for third parties who are interested in outsourcing a study.

October 22, 2012

Belgian company Biogazelle develops lab products beyond industry standards

Bio-Rad Laboratories recently launched a new product line that was designed in conjunction with the Belgian company Biogazelle. The new product line consists of 20,000 individual real-time PCR assays, known as PrimePCR assays, all of which have been validated beyond international lab standards by Biogazelle.

June 6, 2011

Biogazelle presents a revolutionary qPCR based lncRNA profiling platform

lncRNAs represent an emerging important class of regulatory transcribed elements. The study of lncRNAs is timely and relevant, because of their implication in important cellular processes, through new modes of action. The lncRNA genes are generally low abundant, which is exactly why there is a genuine need for a platform with ultimate sensitivity superseding microarray based platforms.